Novo Nordisk has partnered with OpenAI to integrate artificial intelligence across drug discovery, manufacturing, and commercial operations. The collaboration focuses on using AI to analyze large, complex datasets, uncover patterns, and identify promising drug candidates more efficiently.
This is expected to significantly shorten the time required to move treatments from research to patients. Pilot programs will begin across key business areas, with broader integration planned by 2026.
The initiative reflects a wider shift in the pharmaceutical industry toward AI-led innovation to improve research productivity and patient outcomes.
